Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Antoine Lacassagne
OBJECTIVES:
Primary
* Determine event-free survival of patients with large B-cell lymphoma treated with CHOP-R followed by consolidation therapy.
Secondary
* Determine overall survival.
* Evaluate relapse-free survival for patients achieving complete or partial response.
* Determine the rate of disease progression.
* Determine response rate at the end of study therapy.
* Assess the toxicities of this regimen.
OUTLINE: This is a multicenter study.
* Induction therapy: Patients receive the CHOP-R regimen comprising doxorubicin hydrochloride IV, vincristine IV, cyclophosphamide IV, and rituximab IV on day 1 and prednisone IV on days 1-5. Treatment repeats every 2 weeks for 2 courses.
Patients who achieve complete or partial response, as assessed by PET/CT scan, receive a third course of induction therapy.
* Consolidation therapy: Patients receive rituximab IV on days -8 to 0 and yttrium Y 90 ibritumomab tiuxetan IV on day 0.
Age
65–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed large B-cell lymphoma
* Stage I, II, III, or IV disease
* Bone marrow or lymph node involvement by small cell lymphoma allowed
* No serious, progressive pathology (at investigator's discretion)
CD20-positive disease
Measurable disease
No prior indolent lymphoma, treated or not
No meningeal or CNS lymphoma
PATIENT CHARACTERISTICS:
International prognostic index \< 2 (adjusted for age)
Life expectancy \> 3 months
ALT and AST ≤ 2.5 times upper limit of normal
Bilirubin ≤ 30 mmol/L
Creatinine ≤ 150 μmol/L
HIV, hepatitis B virus, and hepatitis C virus negative (unless after vaccine)
No contraindication to chemotherapy or immunotherapy
No cancer in the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix
No contraindication to a venous catheter
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
At least 30 days since prior and no other concurrent investigational treatment
No prior therapy
No concurrent participation in another clinical study